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to the pharmaceutical industry by the NICE initiative.
Although it remains a fairly recent innovation, it would
appear to be timely to undertake an initial assessment of
its implications, both for the pharmaceutical industry and
for national health systems. CONCLUSIONS: The nature
and extent of the learning process through which NICE
has progressed will be explored, together with the current
state of the art with regard to NICE evaluation. In addi-
tion, the potential beneﬁts that arise to health services
from a NICE-style appraisal process will be presented.
Methods by which the clinical and economic evaluations
can be integrated will be presented.
PHP33
EVALUATION AND SELECTION OF MEDICAL
HEALTH TECHNOLOGIES: A GROUP DECISION
SUPPORT SYSTEM (GDSS)
Cantor E, Shtub A
Israel Medical Association, Ramat-Gan, Israel
OBJECTIVES: To select medical technologies that should
be provided to the general public under the National
Health Law. The rapid development of new technologies
and the limited budget of the health care system make the
selection process difﬁcult. The research focused on the
Israeli National Health Care System that faces budgetary
constraint. Once a year a ﬁxed budget has to be allocated
among a set of candidate technologies. The constraint
imposed by the ﬁxed budget must be taken into account
in the decision-making process. METHODS: We devel-
oped a Group Decision Support System based on a 
three-dimensional model: 1) Beneﬁt (measured by the
effectiveness of each technology); 2) Risk (measured by
EBM); and 3) Cost: Based on the Analytical Hierarchy
Process (AHP) methodology, a set of criteria was devel-
oped by a group of medical experts, economists, patient
representatives, sociologists, law experts and ethical
experts. EBM was used to assess the Risk (knowledge
gap) associated with each alternative. While Cost was
estimated by explicit market price of the technology in
consideration. RESULTS: A set of candidate medical
technologies evaluated by the proposed methodology
revealed a clear Pareto distribution. The proposed
methodology helped the decision-makers focus on the
most promising technologies out of a total 193 technolo-
gies proposed. CONCLUSIONS: The proposed method-
ology helped decision makers by focusing their attention
on the most promising medical technologies based on pre-
deﬁned objective set of criteria. The decision process is
more effective and it achieves higher efﬁciency by using
the Group Decision Support System (GDSS).
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The accuracy and reliability of genetic tests has been
rapidly improving, while the cost of such tests is becom-
ing more affordable. The implications of this are poten-
tially drastic: individuals will have access to information
about their genetic predispositions, allowing them to alter
their decisions accordingly. One consideration in this is
the demand for life insurance: an individual at genetic risk
may be inclined to purchase more life insurance in order
to protect her family’s future; however, insurance com-
panies may also try to exclude “bad genetic risks”, assum-
ing they have access to that information. Both actions
lead to adverse selection and inefﬁciency problems in the
insurance market. This paper focuses on the implica-
tions of genetic testing for breast cancer genes (BRCA1
and BRCA2) on life insurance markets. Mutations on
BRCA1/2 genes are not a deﬁnite predictor of breast
cancer: there is roughly an 85% lifetime probability that
a carrier will develop the disease, moreover, individuals
can use prophylaxis and thereby considerably lower their
risk of developing breast cancer. Hence, the interpretation
of a positive test result is complicated, both for the indi-
vidual and for the insurance company. OBJECTIVE: This
paper looks at several scenarios (including different 
age and risk groups and income levels) to determine the
impact on the demand for life insurance by women at
genetic risk for breast cancer. METHOD: The methodol-
ogy used is a microeconomic framework where individ-
uals maximise their expected utility as a function of
insurance purchases, and the insurance company may or
may not know the results of the genetic test. RESULTS:
The results show that women with higher incomes and
higher levels of risk aversion are more likely to purchase
life insurance. CONCLUSIONS: However, women that
are less risk averse and have lower incomes tend to under-
insure themselves, underscoring the need to ensure an
adequate perception of own-risk.
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OBJECTIVE: As part of an “outcomes program” on
smoking cessation, we thought it relevant to evaluate in
smokers under 25 years of age the obstacles to cessation,
the level of dependency, the knowledge of tobacco depen-
dency and the propensity to pay for cessation treatment.
METHOD: For this pilot phase, an anonymous ques-
tionnaire was distributed in the “Etudiant” supplement
of a French regional weekly newspaper. RESULTS:
Obstacle to cessation: lack of willpower (51%), enjoy-
ment of smoking (32%), force of habit (46%) The level
of dependency on tobacco was evaluated using the Fager-
ström test: 48% had low dependency, 48% moderate
